As the biopharma industry increases its focus on rare diseases, the global drug pipeline is rapidly filling with a sophisticated new wave of orphan products. Highly sensitive and increasingly complex, these products are often produced in small-scale batches that put CDMOs’ technical and economical expertise to the test.
Vetter and Syntegon are rising to the challenge, and pursuing a new industry standard in small-batch manufacturing. With combined expertise in fill-and-finish, system process design, and plant technology, our teams are collaborating on an innovative, flexible, cGMP-compliant filling concept for small batch sizes.
Learn more in this new industry article from Arno Schroff, Director Site & Plant Development at Vetter.